In a randomized open-label trial, 99 ND-CKD patients with IDA (Hb ≤ 12 g/dL, ferritin ≤ 100 ng/mL, TSAT ≤ 25%) were assigned (2:1) to receive oral SI (30 mg/day) for 3 months or a total dose of 1000 mg of IV FG (125 mg/week), and they were followed-up for 4 months [50]. The gene discussed is GSTM1; the disease is chronic kidney disease.